Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023
Just apply a small amount to an out-of-the-way spot, like behind your ear, and wait 24 hours to see how your skin reacts
My skin is literally GLOWING
In a large study of over 18,000 patients, rates of gastrointestinal side effects were similar between tirzepatide and semaglutide users, with no significant difference between the drugs
"Truman Theodore Hanks, Born 12/26/1995 in California | CaliforniaBirthIndex.org"
Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity